TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7798463
Drug: Simulated exclusion
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulated exclusion criteria (borderline personality disorder, drug/alcohol dependence, and others)
Study: 26888806
Drug: rhBNP administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhBNP administration (1.5 µg/kg bolus intravenous injection followed by 0.0075-0.03 µg·kg(‐1)·min(‐1) for up to 120 hours)
Study: 26888806
Drug: NIT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIT treatment (10-100 µg/min intravenous infusion for 120 hours)
Study: 23963331
Drug: G‐CSF (135
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (135 µg/kg body weight intravenous over 72 hours)
Study: 18326136
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia with propofol and remifentanil (Group R)
Study: 8869763
Drug: Therapeutic dose
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic dose of morphine
Study: 8869763
Drug: Pupillometric study
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pupillometric study with morphine
Study: 1290604
Drug: Dentin bonding
Normalized name: SKIN BOND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dentin bonding agents (8 different types)
Study: 6427027
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate alone (50 mg/day, cycle days 5 to 9)
Study: 25283499
Drug: Telbivudine preemptive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine preemptive therapy
Study: 21139575
Drug: No antiviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiviral therapy
Study: 22404442
Drug: LA-CT (lansoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: LA-CT (lansoprazole 30 mg b.i.d. + amoxicillin 1 g b.i.d. for 1 week, followed by lansoprazole 30 mg b.i.d. + clarithromycin 500 mg b.i.d. + tetracycline 500 mg q.i.d. for 2nd week)
Study: 22404442
Drug: LA-CM (lansoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: LA-CM (lansoprazole 30 mg b.i.d. + amoxicillin 1 g b.i.d. for 1 week, followed by lansoprazole 30 mg b.i.d. + clarithromycin 500 mg b.i.d. + metronidazole 500 mg t.i.d. for 2nd week)
Study: 18080055
Drug: Delayed-release oral
Normalized name: Prevacid 1 MG/ML Delayed-Release Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release oral mesalamine 2.4 g/day (400 mg tablet)
Study: 18080055
Drug: Delayed-release oral
Normalized name: Prevacid 1 MG/ML Delayed-Release Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release oral mesalamine 4.8 g/day (800 mg tablet)
Study: 18080055
Drug: Delayed-release oral
Normalized name: Prevacid 1 MG/ML Delayed-Release Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release oral mesalamine 2.4 g/day (400 mg tablet) in moderate disease subgroup
Study: 18080055
Drug: Delayed-release oral
Normalized name: Prevacid 1 MG/ML Delayed-Release Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release oral mesalamine 4.8 g/day (800 mg tablet) in moderate disease subgroup
Study: 19888035
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol (2 mg)
Study: 11341495
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (50 microg)
Study: 412995
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of glucose, fructose and xylitol (1:2:1 ratio)
Study: 27089154
Drug: Cognitive enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive enhancement therapy (n = 22)
Study: 19412196
Drug: biologic agents
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: biologic agents
Study: 17898955
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (oral intake of vitamin C and E, external application of quban powder)
Study: 7756226
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with 2.7 g of MaxEpa daily (1.62 g of eicosapentaenoic acid and 1.08 g of docosahexaenoic acid)
Study: 2156885
Drug: Dexamethasone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.5 mg daily)
Study: 319816
Drug: Naloxone 0.4
Normalized name: NALOXONE 0.4MG/0.4ML AUTOINJECTOR,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone 0.4 mg
Study: 25762759
Drug: Computerized motivational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized motivational feedback at baseline, 3 months, and 6 months; 12 weeks of cessation counseling and nicotine patches
Study: 22463614
Drug: sPLA2 threshold
Approvals — FDA: no, EMA: no, PMDA: no
Description: sPLA2 threshold level ≥ 48 ng/ml
Study: 15226332
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (CRT)
Study: 11984215
Drug: Atorvastatin (A)
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin (A) 20 mg/day
Study: 11984215
Drug: Pravastatin (P)
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pravastatin (P) 20 mg/day + Gemfibrozil (G) 1200 mg/day
Study: 11984215
Drug: Simvastatin (S)
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin (S) 20 mg/day + Gemfibrozil (G) 1200 mg/day
Study: 11984215
Drug: Pravastatin (P)
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pravastatin (P) 20 mg/day + Ciprofibrate (C) 100 mg/day
Study: 11984215
Drug: Simvastatin (S)
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin (S) 20 mg/day + Ciprofibrate (C) 100 mg/day
Study: 2375883
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (1500 mg d‐1)
Study: 497093
Drug: Sustained-release oral
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release oral procainamide preparation 1
Study: 497093
Drug: Sustained-release oral
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release oral procainamide preparation 2
Study: 30910320
Drug: β blockers
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: β blockers (propranolol up to 160 mg twice a day or carvedilol ≤25 mg/day)
Study: 29135115
Drug: Ipilimumab 3mg/kg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab 3mg/kg, administered with short 30-min i.v. infusion every 3 weeks, total of 4 doses
Study: 26320827
Drug: Modafinil 300mg
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil 300mg daily
Study: 23384300
Drug: Esmolol (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (0.05 mg·kg(‐1) ·min(‐1) after tracheal intubation, 0.3 mg·kg(‐1) ·min(‐1) during CPB, 0.03‐0.05 mg·kg(‐1) ·min(‐1) until the end of surgery)
Study: 20938439
Drug: Low-fat, high-complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat, high-complex carbohydrate (LFHCC) diet supplemented with long chain n-3 polyunsaturated fatty acids (LC n-3 PUFAs) (1.2 g per day) for 12 weeks
Study: 17224858
Drug: Citalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (10 mg/day initially, increased to 20 mg/day after 1 week)
Study: 17224858
Drug: Citalopram +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram + HT (10 mg/day initially, increased to 20 mg/day after 1 week)
Study: 16595221
Drug: 0.15 mg
Normalized name: iodine 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg of desogestrel plus 0.030 mg of ethinyl E2 daily for 12 months
Study: 16595221
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of cyproterone acetate plus 0.035 mg of ethinyl E2 daily for 12 months
Study: 12883329
Drug: Oxygen administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen administration for 1 hour
Study: 11023928
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg/d for 3 days and then 500 mg/wk for 3 months
Study: 9273524
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of intravenous opiate injections and administration of methadone
Study: 9273524
Drug: Continued injecting
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued injecting drug use (Control group)
Study: 1642909
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose extradural morphine
Study: 1642909
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of morphine and clonidine
Study: 26225497
Drug: Sugammadex 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 4 mg/kg
Study: 30169407
Drug: Sugammadex 2
Normalized name: sugammadex 200 MG in 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 2 mg/kg and Sugammadex 4 mg/kg
Study: 23150144
Drug: Risedronate 75
Normalized name: risedronate 75 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 75 mg on 2 consecutive days each month (2CDM)
Study: 9467547
Drug: Risedronate 5
Normalized name: risedronate 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 5 mg daily
Study: 19476402
Drug: Risedronate 75
Normalized name: risedronate 75 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 75 mg 2CDM
Study: 21496415
Drug: Leflunomide (LEF)
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leflunomide (LEF) at a daily dose of 20 mg
Study: 21496415
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) at a mean dose of 11.7±2.6 mg/week
Study: 18510807
Drug: DHA (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA (800 mg/day)
Study: 19447020
Drug: Lutein (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein (12 mg/day)
Study: 18510807
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of DHA and lutein
Study: 17130504
Drug: Intensive diabetes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive diabetes treatment during the DCCT
Study: 17130504
Drug: Conventional diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional diabetes treatment during the DCCT
Study: 17130504
Drug: Prior intensive
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior intensive diabetes treatment
Study: 11516093
Drug: Lenograstim (glycosylated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenograstim (glycosylated recombinant human G‐CSF) 5 microg per kg body weight subcutaneously daily from day 8 after starting chemotherapy.
Study: 8381931
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion (40 mU.m‐2.min‐1)
Study: 8381931
Drug: Perindopril (converting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (converting enzyme inhibitor)
Study: 28949012
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg once daily (OD) PF-04965842
Study: 28949012
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg OD PF-04965842
Study: 28949012
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg twice daily (TD) PF-04965842
Study: 23878319
Drug: Vaccine-induced T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine-induced T cells targeting ≥3 gag peptides
Study: 23878319
Drug: Vaccine-induced T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine-induced T cells
Study: 20034487
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (1 g/day) for 3 months
Study: 16737416
Drug: Lansoprazole 15
Normalized name: lansoprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 15 mg/day for 2 weeks
Study: 6373156
Drug: Glaucine syrup
Normalized name: glaucine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glaucine syrup 30 mg 3-times daily for 7 days
Study: 6373156
Drug: Codeine syrup
Normalized name: TUSSIREX W/CODEINE SYRUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine syrup 30 mg 3-times daily for 7 days
Study: 6373156
Drug: Glaucine capsules
Normalized name: glaucine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glaucine capsules 30 mg 3-times daily for 28 days
Study: 29753693
Drug: 5-aminolevulinic acid
Normalized name: 5-aminolevulinic acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminolevulinic acid (ALA) 600 mg and sodium ferrous citrate (SFC) 942 mg
Study: 30931663
Drug: Palacos R
Normalized name: R-348
DrugBank: R-348 (DB06321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palacos R + G
Study: 24710342
Drug: Corticosteroids treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids treatment within 24 hours after admission
Study: 19308727
Drug: Denosumab 60
Normalized name: denosumab 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 60 mg subcutaneously every 6 months
Study: 12881343
Drug: Partial Tenon's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial Tenon's capsule resection with adjunctive mitomycin C (MMC)
Study: 12881343
Drug: Ahmed glaucoma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ahmed glaucoma valve implant without PTCR (control group)
Study: 10966009
Drug: Abciximab treatment
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab treatment during coronary artery bypass grafting
Study: 1567745
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (S-I)
Study: 1567745
Drug: Golytely solution
DrugBank: Sodium sulfate (DB09472)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Golytely solution (S-II)
Study: 1567745
Drug: Digestive irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digestive irrigation with antibiotics
Study: 2865218
Drug: Bopindolol 1
Normalized name: bopindolol 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bopindolol 1 mg (BP1)
Study: 2865218
Drug: Bopindolol 2
Normalized name: bopindolol
DrugBank: Bopindolol (DB08807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bopindolol 2 mg (BP2)
Study: 2865218
Drug: Lorazepam 2.5
Normalized name: lorazepam 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 2.5 mg (LR)
Study: 2865218
Drug: Butalbital 75
Normalized name: Butalbital
DrugBank: Butalbital (DB00241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Butalbital 75 mg (BT)
Study: 24885942
Drug: Lanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanthanum carbonate 3000 mg/day
Study: 15857067
Drug: Aqueous solution
Normalized name: Zephiran Chloride 1:750 Antiseptic Aqueous Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous solution of hydroxy-ethyl-methacrylate and glutaraldehyde (HEMA-G)
Study: 15857067
Drug: Both agents
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both agents (NaF and HEMA-G)
Study: 15857067
Drug: Teeth requiring
Normalized name: Coptis teeta root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teeth requiring repeat dosage
Study: 11405503
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no thrombolytic therapy)
Study: 9874451
Drug: EEP (etoposide
Approvals — FDA: no, EMA: no, PMDA: no
Description: EEP (etoposide 120 mg/m2, epirubicin 30 mg/m2, cisplatin 40 mg/m2 on Days 1 and 8)
Study: 9874451
Drug: FEP (5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEP (5-fluorouracil 600 mg/m2, epirubicin 60 mg/m2, cisplatin 80 mg/m2 on Day 1)
Study: 8594118
Drug: Refrigerant topical
Normalized name: Refrigerant 114
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refrigerant topical anesthetic
Study: 8594118
Drug: Placebo topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo topical spray
Study: 19351782
Drug: No-spray control
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-spray control
Study: 38680
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg atropine
Study: 38680
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg hyoscine
Study: 38680
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg glycopyrronium
Study: 23794465
Drug: Prednisone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (1 mg·kg(‐1) daily for up to 10 days)
Study: 18236139
Drug: Silymarin (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin (140 mg) three times per day for 5 days
Study: 14658947
Drug: Various NSAIDs
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Various NSAIDs (including aspirin and sulindac)
Study: 21055739
Drug: CDB-2914 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDB-2914 (10 mg)
Study: 10783359
Drug: CDB-2914 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDB-2914 (50 mg)
Study: 10783359
Drug: CDB-2914 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDB-2914 (100 mg)
Study: 10783359
Drug: CDB-2914 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDB-2914 (all doses)
Study: 6696210
Drug: Ispaghula suspension
Normalized name: ISPAGHULA
DrugBank: Plantago ovata seed (DB14585)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ispaghula suspension (oral challenge)
Study: 31227014
Drug: Empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 mg daily for 90 days
Study: 24378958
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg doxycycline daily for 4 months
Study: 22157087
Drug: Mustard preparation
Normalized name: MUSTARD
DrugBank: White mustard seed (DB15606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mustard preparation (20 g, 25 mg total ITC) daily for 4 days
Study: 20400377
Drug: NGX-4010 (8%
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGX-4010 (8% w/w capsaicin patch), applied for 60 minutes
Study: 18568273
Drug: DTaP-IPV//PRP approximately
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-IPV//PRP approximately T + hepatitis B vaccine at 0, 6, and 14 weeks
Study: 18568273
Drug: DTaP-IPV//PRP approximately
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-IPV//PRP approximately T + hepatitis B vaccine at 6, 10, and 14 weeks
Study: 18568273
Drug: DTaP-IPV//PRP approximately
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-IPV//PRP approximately T + hepatitis B vaccine
Study: 16053121
Drug: Breath therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breath therapy
Study: 7109988
Drug: Remote mental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote mental healing treatment by healers
Study: 7109988
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (normal medical treatment)
Study: 7109988
Drug: Healers' treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healers' treatment
Study: 27460638
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with anthracyclines
Study: 27460638
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy without anthracyclines
Study: 23778382
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day amisulpride plus 800 mg/day sulpiride
Study: 23778382
Drug: 800 mg/day
Normalized name: RibaTab 800 mg/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg/day amisulpride
Study: 17981885
Drug: 0.55 g/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.55 g/kg/day protein diet
Study: 17981885
Drug: 0.8 g/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g/kg/day protein diet
Study: 8729588
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg/day combined with bezafibrate 400 mg/day
Study: 8729588
Drug: Fluvastatin 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 10 mg combined with cholestyramine 8 g/day
Study: 8729588
Drug: Fluvastatin 20
Normalized name: fluvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 20 mg combined with cholestyramine 8 g/day
Study: 8729588
Drug: Fluvastatin 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 10 mg combined with cholestyramine 8 g/day after 8 weeks
Study: 8729588
Drug: Fluvastatin 20
Normalized name: fluvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 20 mg combined with cholestyramine 8 g/day after 8 weeks
Study: 8729588
Drug: Niacin monotherapy
Normalized name: Niacin
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin monotherapy
Study: 8729588
Drug: Fluvastatin 20
Normalized name: fluvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 20 mg combined with niacin (3 g/day)
Study: 1678271
Drug: 14 mg
Normalized name: iodine 0.14 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 mg transdermal patch
Study: 1678271
Drug: 7 to
Normalized name: NP-27 Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 to 21 mg transdermal patches
Study: 1678271
Drug: transdermal patches
Normalized name: MENTHOL 0.3 g in 100 TOPICAL PATCH [Aroamas Cot Nicotine Transdermal Patches]
Approvals — FDA: no, EMA: no, PMDA: no
Description: transdermal patches
Study: 17242633
Drug: Transdermal 17beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17beta‐estradiol at a dose of 50 mug/day and nomegestrol at a dose of 5 mg/day (group B, n = 22)
Study: 11159619
Drug: Streptococcal spray
Normalized name: Streptococcal fibrinolysin
DrugBank: Streptokinase (DB00086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptococcal spray